Anakinra as a Treatment for Hydradenitis Suppurativa
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, proof-of-concept research study to assess the effectiveness of
anakinra in the treatment of patients with hidradenitis suppurativa (HS). The planned
intervention is to provide about 6 HS patients with anakinra 100mg daily injections to
administer subcutaneously for 8 weeks. Then, the study subjects will be followed for a
further 8 weeks to monitor for relapse of HS.